Column: Comparative-research provision draws major criticism

02/12/2009 | Washington Post (tiered subscription model), The

The $1.1 billion fund allocated for comparative-effectiveness research in the economic-stimulus package has drawn criticism from some health experts and media members who say the move ultimately will allow the government to dictate what medicines people should or should not receive, writes Washington Post columnist Steven Pearlstein. Although this is unlikely if the research is carried out in a "disciplined, scientific way," the concerns should serve to warn the Obama administration of how health care reform likely will become a "vicious and divisive" issue, Pearlstein writes.

View Full Article in:

Washington Post (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health